Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

This study tests a new drug called xaluritamig given before surgery (called neoadjuvant therapy) in people with localized prostate cancer who are scheduled for radical prostatectomy (surgical removal of the prostate). The goal is to see whether this drug can help shrink or eliminate cancer cells before surgery. **You may be eligible if...** - You are scheduled to have your prostate surgically removed - You have been diagnosed with prostate adenocarcinoma confirmed by biopsy - Your cancer is localized (has not spread to distant organs) - You are in good physical health **You may NOT be eligible if...** - You have a neuroendocrine or small cell type prostate cancer - You have already received hormone therapy, chemotherapy, or radiation for this cancer - You have significant heart, kidney, or liver problems - You are on medications that interfere with the study drug Talk to your doctor to see if this trial is right for you.